Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
NCT05745233Enrolling by invitation
- Sponsor
- China Medical University Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and pembrolizumab in malignant ascites, sponsored by China Medical University Hospital. Primary endpoint: Response rate up to 2 years. Started Jan 2021; status: enrolling by invitation.
02
Drugs
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT05745233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745233.